This trio of new enCORE 17 functions will take your clinical assessment capability to the next level.

You already rely on enCORE for world-class clinical assessment. So now, we're pleased to announce the latest upgrade – to enhance DXA capability even more. With enCORE 17, you'll particularly benefit from three features that focus on **Atypical Femur Fracture (AFF)**, **Sarcopenia**, and **Cybersecurity** measures.

And, of course, your enCORE package will continue to offer the comprehensive, user-friendly features you already rely on that provide:

- Clinical confidence; the precision across a broad range of patient sizes and conditions
- The productivity-enhancers that keep you cost effective
- The data management and security you require

Just in case you are a few releases of enCORE software behind, here is an overview of features that we have released over the past couple of years:

Feature/SW version	2011 v13	2012 v14	2013 v15	2014 v16	2016 v17
Skeletal Health	FRAX® Spine Geometry	Dose Reporting	OneScan JSBMR Ref	Ortho Knee Peds TB	AFF
Body Composition	CoreScan	Advanced Body Composition			Sarcopenia
Connectivity	DICOM®		EMR Suppliers ICD-10 Codes		
Acquisition	Supine Forearm			Seated Forearm Over Table Weight	
Database	Peds BMDCS Reference	NHANES	SQL Server	MUDBA 40	
PC OS/Security	W-XP/W7 32 Bit Microsoft Security Patches	Microsoft Security Patches	Application Access Control	W7 – 64 Bit	FDA Cybersecurity

Imagination at work

JB40748US

GE Healthcare

Healthy aging. It's vital.

enCORE 17

The leading edge of DXA applications



enCORE 17 adds these **three** crucial functions to your existing system:

1 For AFF analysis, a quick (yet thorough) way to quantify focal thickening of the lateral cortex

AFFs are an increasing concern for patients and clinicians alike due to the potential connection with long-term Bisphosphonate use. Your enCORE 17 upgrade offers optional AFF software – a potent tool for Prodigy™ and Lunar iDXA™ systems. This feature allows you to quantify focal thickening of the lateral cortex (along the entire femoral shaft) to the knee.

We have created a "Beaking Index," that is a measure of the magnitude of the increase in the cortical width (mm) at the location of the localized periosteal reaction. Beaking is a key to assessing the presence of a potential AFF. This analysis can quickly be run on a single femur scan (for both BMD and AFF); you'll be able to trend the serial measurements graphically, allowing for visualization of any potential AFF sites.

It's comprehensive, as well: the software automatically connects with the entire patient database, to offer a comparative analysis with past exams, even your standard length femur scans. BMD results from typical femur scans and proximal femurs are equivalent.

AFF Analysis





Sarcopenia



2 For Sarcopenia, a complete assessment package that allows the use of either a published or custom definition

With our aging population, Sarcopenia is a common concern. We've developed enCORE's optional Sarcopenia Toolset to facilitate diagnosis and monitoring of Sarcopenia on your Prodigy or Lunar iDXA system. It's a comprehensive way to measure and report the patient's Appendicular Lean Mass (ALM) seamlessly with Muscle Strength and Muscle/Physical Performance metrics...for a complete, integrated Sarcopenia assessment. From there, you enjoy great flexibility. You can choose between the common published definitions, or create a custom definition, to support your clinical decision-making.

3 For superior cybersecurity, a robust suite of built-in safety features that meet federal standards

Our DXA Bone Densitometers with enCORE v17 were designed to meet the cybersecurity control measures as defined in recently published FDA cybersecurity guidance. Following the FDA's guidance, GE Healthcare put together a Design Engineering Privacy and Security (DEPS) process to ensure that cybersecurity is maintain throughout the product's lifecycle.

As a result the cybersecurity vulnerability of our DXA systems is minimized to an acceptable level. (See our User Manual Security section for additional details).

Please ask for our Manufacturer Disclosure Statement for Medical Device Security (MDS2).

MDS2 is one of most critical documents for you during the procurement stage. MDS2 facilitates the review and analysis of the large volume of security-related information supplied by manufacturers for devices on the customer's inventories. MDS2 also allows medical device manufacturers like GE Healthcare to publish the basic security and privacy properties of a specific medical device including operating systems, type of network connection, the ability of the operator to install Antivirus software, or what PHI (Protected Health Information) is stored on the device and whether it is transient or permanent. GE Healthcare is committed to provide the MDS2 using latest released revision of the form to our customers to ensure customers have the most current information as well.

Cybersecurity